<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05093855</url>
  </required_header>
  <id_info>
    <org_study_id>STS-BDB001-08</org_study_id>
    <nct_id>NCT05093855</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)</brief_title>
  <official_title>A Multicenter, Open-label, Phase II Study to Explore Efficacy and Safety of BDB-001 Injection in Subjects With Moderate to Severe Hidradenitis Suppurativa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Staidson (Beijing) Biopharmaceuticals Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Defengrui Biotechnology Co. Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Staidson (Beijing) Biopharmaceuticals Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore whether BDB-001 Injection is effective and safe in&#xD;
      the treatment of moderate to severe hidradenitis suppurativa(HS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in INAPP (Inflammatory Nodules, Abscesses, Pyorrhea, Pain VAS) score relative to baseline</measure>
    <time_frame>Week 8</time_frame>
    <description>INAPP Score=(Inflammatory Nodule Count) + (Abscess Count*2) + (Pyorrhea *2)+（Pain VAS).The higher the score the more severe is the disease/worse is the outcome.&#xD;
Pain VAS：This is a segmented numeric version of the visual analog scale in which a respondent selects a whole number (0-10) that best reflects the intensity of their pain. The scale title for the VAS is points. The minimum score is 0 points (No skin pain), and the maximum score is 10 points (Skin pain as bad as you can imagine). The higher the score the more severe is the disease/worse is the outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in International Hidradenitis Suppurativa Severity Score System (IHS4) score from Day 0 by time point</measure>
    <time_frame>From Day 0 until Day 56</time_frame>
    <description>The International Hidradenitis Suppurativa Severity Score 4 (IHS4: developed by the European Hidradenitis Suppurativa Foundation Investigator Group)，IHS4 Score=(Nodule Count) + (Abscess Count*2) + (Draining Tunnel Count *4).&#xD;
IHS4 score uses a range grades:&#xD;
Mild=0-3; Moderate=4-10; Severe ≥11.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in modified Sartorius Score (mSS) from Day 0 by time point</measure>
    <time_frame>From Day 0 until Day 56</time_frame>
    <description>The mSS is a summation of HS lesions based on a number of factors including anatomical region, number and type of lesions, distance between relevant lesions and lesions clearly separated by normal skin in each region measured as HS clinical parameters. The scale title for mSS is points. The mSS has a minimum value of 0 and no upper limit. The higher the score the more severe is the disease/worse is the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hidradenitis Suppurativa Clinical Response (HiSCR) from Day 0 by time point</measure>
    <time_frame>From Day 0 until Day 56</time_frame>
    <description>The definition for response to treatment based on HiSCR relative to Baseline was: at least 50% reduction in abscesses and inflammatory nodule (AN) count (over all anatomical regions) with no increase in number of abscesses and in number of draining fistulas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hidradenitis suppurativa-Physician Global Assessment (HS-PGA) score from Day 0 by time point</measure>
    <time_frame>From Day 0 until Day 56</time_frame>
    <description>Hidradenitis Suppurativa - Physician's Global Assessment (HS-PGA)classifies patients' severity into six categories:clear, minimal, mild, moderate, severe, and very severe, based on the number and quality of inflammatory lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dermatology Life Quality Index (DLQI) score from Day 0 by time point</measure>
    <time_frame>From Day 0 until Day 56</time_frame>
    <description>A score is documented for each of the 10 DLQI items, ranging from 0 to 3 for each item. The scale title for DLQI is points. The total score is the sum of the responses to all 10 DLQI items, ranging from the minimum of 0 points to the maximum of 30 points. A higher score corresponds to worse health related quality of life/outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of BDB-001 injection in the treatment of patients with HS will be assessed</measure>
    <time_frame>From Day 0 until Day 77</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hidradenitis Suppurativa</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BDB-001 Injection dosage and method of administration: Day 0, 7, 14, 21, 28, 35, 42, 49 with dose of 800mg (80mL). Basic treatment is also needed, including dressing and dressing change, as well as external therapeutic drugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BDB-001 Injection</intervention_name>
    <description>Single IV infusions of BDB-001 Injection diluted in sodium chloride</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who signed the informed consent to participate in the STS-BDB001-06 clinical&#xD;
             study and completed all follow-up of the study as required by the protocol, or who&#xD;
             withdrew early due to treatment failure or other objective reasons and completed the&#xD;
             early withdrawal visit (at least 4 weeks of treatment)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Never participated in the clinical study of STS-BDB001-06；&#xD;
&#xD;
          -  Subjects withdrew from the STS-BDB001-06 clinical study due to an intolerable adverse&#xD;
             event related to the study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Du Zhouqi</last_name>
    <phone>+86 17600505723</phone>
    <email>duzhouqi@staidson.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Hang</last_name>
      <phone>+86 13693058190</phone>
      <email>drlihang@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100144</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang Baoxi</last_name>
      <phone>+86 13911001336</phone>
      <email>wangbx@vip.126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Hongzhong</last_name>
      <phone>+86 13693583080</phone>
      <email>jinhongzhong@263.net</email>
    </contact>
    <contact_backup>
      <last_name>Chen Rui</last_name>
      <phone>+86 13811790704</phone>
      <email>chenrui04@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>51063</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lai Wei</last_name>
      <phone>+86 18922102962</phone>
      <email>drlaiwei@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital, Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Ji</last_name>
      <phone>+86 15674924749</phone>
      <email>993161577@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Min</last_name>
      <phone>+86 15951862791</phone>
      <email>drlimin@sina.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sun Qing</last_name>
      <phone>+86 18560082626</phone>
      <email>sunqing7226@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu Jinhua</last_name>
      <phone>+86 13818978539</phone>
      <email>xjhhsyy@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geng Songmei</last_name>
      <phone>+86 13060423612</phone>
      <email>gsm312@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiang Xian</last_name>
      <phone>+86 18980601693</phone>
      <email>jennyxianj@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
    <mesh_term>Hidradenitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

